Takeaway: SAMA / CLVR is on the Hedgeye Long Bias list.

Cannabis Subscribers CLICK HERE for event details (includes video, dial-in and materials link). We will not have a dial in for this event.

We will be hosting a conversation with Kyle Detwiler, the Clever Leaves CEO, on Thursday, December 3rd, at 2 PM.  Clever Leaves is expected to close its merger with Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA) in Q4 under the new ticker "CLVR." It's anticipated that CLVR will be listed on the NASDAQ.

Clever Leaves is a multinational operator and licensed producer of pharmaceutical-grade cannabinoids with its primary operations in Colombia. We are bullish on SAMA/CLVR and believe in the company's opportunity: the company is early stage, the global cannabis opportunity is significant, and Clever Leaves appears to be positioned for material revenue growth coupled with a very desirable cost structure in 2021 and beyond.    

  • The leader in low-cost medical-focused cannabis cultivation and extraction
  • Thoughtfully constructed, a vertically integrated multinational operator (MNO)
  • Pharmaceutical-grade, EU GMP-certified production authorized for export
  • Purpose-built for significant growth, profitability, and operating leverage
  • Talented and experienced leadership with operational and regulatory expertise
  • Attractive valuation.

Kyle Detwiler bio:

  • Founded Northern Swan Holdings in 2017, which merged with Clever Leaves in 2019
  • Co-founded Silver Swan Capital, an investment firm focused on niche and under-followed sectors Former Principal at Blackstone's Tactical Opportunities Fund
  • A former investment professional at KKR focused on the oil and gas, energy, natural resource, and health care sectors
  • MBA from Harvard Business School